A new study published in the Nature Medicine journal has shown that Tetra Therapeutics’ Alzheimer’s investigational disease drug improves language and learning ability in adults diagnosed with Fragile X Syndrome. Fragile X Syndrome is a genetic condition that causes mild to severe intellectual disability, and presents in both females and males. The drug, known as BPN14770, is designed to selectively inhibit phosphodiesterase-4D which in turn increases levels of an essential signaling molecule called cAMP. Last year, Tetra found from a Phase II, placebo-controlled clinical trial that the novel drug significantly improved cognition for 30 patients with Fragile X Syndrome.
Read more here.